FDA Panel: Naproxen not safer than other painkillers


An FDA advisory committee has voted 16-9 that there is not enough evidence to assert that the anti-inflammatory painkiller Naproxen, which Bayer (BAYRY) sells as Aleve, is safer for the heart than rival drugs.

The vote means that Bayer and other sellers of Naproxen won't have a marketing advantage over other painkillers such as Advil, Ibuprofen and Celebrex.

The FDA had organized the meeting after epidemiologists who work at the agency said there was evidence to show that Naproxen is safer.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs